Sun Pharmaceutical Industries Ltd. received a warning letter from the US health regulator for its Dadra facility over a violation of manufacturing norms.
The warning letter by the US Food and Drug Administration summarises violations with respect to current good manufacturing practice regulations, the company said in an exchange filing on Wednesday.
The contents of the warning letter issued by the US health regulator shall be made public in due course, it added.
This intimation is further to our communication dated Apr. 11, 2024, about the Dadra facility receiving OAI status from the USFDA.
On Apr. 11, Sun Pharma informed stock exchanges that its Dadra facility had received official action-indicated status from the USFDA.
It followed an inspection at the company's Dadra facility from December 4 to Dec. 15, 2023.
(With Inputs From PTI)
RECOMMENDED FOR YOU
.jpeg.jpg?rect=0%2C0%2C3500%2C1969&w=75)
Piramal Enterprises Q1 Review: CLSA, Citi Raise Targets, But Warn Of Risks — Should You Buy, Sell Or Hold?
Jul 30, 2025
Dr Reddy's Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit
Jul 18, 2025
BSE, NSE Warn Of Online-Bond-Platform Risks; Urge Investors To Do Due Diligence Before Investing
Jul 11, 2025
With Great Control, Come Great Costs — Experts Warn Against Investing In Physical Real Estate
Jul 09, 2025
POPULAR